Clinical trials · Chicago, IL
Unresectable Solid Tumor clinical trials in Chicago
We’re tracking 30 recruiting unresectable solid tumor studies with a site in or near Chicago — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Chicago
- NCT06566079RecruitingPhase 1
Study of ISM6331 for advanced mesothelioma or other solid tumors
This trial tests an experimental drug called ISM6331 for people with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The drug targets a specific cell pathway (Hippo) that may be involved in tumor growth.
Chicago, IllinoisAges 18 years+ - NCT05372614RecruitingPhase 1
Testing trastuzumab deruxtecan and neratinib for HER2-positive cancers
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
Chicago, IllinoisAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Chicago, IllinoisAges 18 years+ - NCT05985161RecruitingPhase 2
Selinexor for wilms tumor and other solid tumors
This trial tests a drug called selinexor for children and young adults with certain types of solid tumors (like Wilms tumor, rhabdoid tumors, MPNST, or others with specific genetic changes) that have come back or not responded to standard treatment. Participants take selinexor pills to see if it can shrink or control their cancer.
Chicago, IllinoisAges 1 year+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Chicago, IllinoisAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Chicago, IllinoisAges Any age - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Chicago, IllinoisAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Chicago, IllinoisAges 18 years+ - NCT06554795RecruitingPhase 1/Phase 2
Testing DB-1419 for advanced solid tumors
This trial tests a new drug called DB-1419 for people with advanced solid tumors that have not responded to other treatments. It is designed to target a protein called B7-H3 on cancer cells, and may help shrink tumors or slow their growth.
Chicago, IllinoisAges 18 years+ - NCT06898450RecruitingPhase 1/Phase 2
Study of new drug NDI-219216 for advanced solid tumors
This study tests a new drug called NDI-219216 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and can help shrink or control the cancer.
Chicago, IllinoisAges 18–99 - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Chicago, IllinoisAges 18 years+ - NCT03715933RecruitingPhase 1
Test drug INBRX-109 for advanced or metastatic solid tumors
This Phase 1 trial tests INBRX-109, a cancer-targeting drug, in people whose solid cancers are locally advanced or spread to other parts of the body. Because it’s Phase 1, the main goal is to see whether it’s safe and how well it can work for different tumor types that meet specific requirements.
Chicago, IllinoisAges 12–85 - NCT04572451RecruitingPhase 1
Radiation with two antibody drugs for advanced, metastatic cancers
This early-phase trial tests whether a focused type of radiation (SBRT) given with anti–PD-1 and an anti–IL-8 antibody is safe in people with advanced cancers that have spread. It also looks for whether this combination might help control tumors at a few treatable spots.
Chicago, IllinoisAges 18 years+ - NCT07359820RecruitingPhase 2
Lirafugratinib for solid tumors with FGFR2 fusion
This trial tests a targeted drug called lirafugratinib for people with advanced solid tumors (not bile duct cancer) that have a specific FGFR2 gene change. The drug blocks the faulty protein from helping the cancer grow.
Chicago, IllinoisAges 18 years+ - NCT06620302RecruitingPhase 1/Phase 2
Adding DT2216 to chemo for relapsed solid tumors and FLC
This trial is testing whether adding a new drug, DT2216, to standard chemotherapy can help treat solid tumors (not starting in the brain) or fibrolamellar carcinoma (FLC) that have come back or not responded to treatment. It's for children, teens, and young adults (ages 1 to 39).
Chicago, IllinoisAges 1–39 - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Chicago, IllinoisAges 1–30 - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Chicago, IllinoisAges 18 years+ - NCT05687110RecruitingPhase 1
Testing novobiocin for tumors with DNA repair gene changes
This Phase 1 study tests whether novobiocin is safe and finds the best dose for people whose tumors have specific DNA repair gene mutations. It may help if your cancer is hard to treat with standard options, including certain patients who already tried PARP inhibitors.
Chicago, IllinoisAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Chicago, IllinoisAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Chicago, IllinoisAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Chicago, IllinoisAges 18 years+ - NCT04665206RecruitingPhase 1/Phase 2
Testing VT3989 for certain advanced cancers
This early-stage trial tests VT3989 in people with specific advanced (metastatic or unresectable) cancers. It may help shrink tumors or slow cancer growth in patients who fit the genetic or diagnosis-specific requirements.
Chicago, IllinoisAges 18 years+ - NCT05732831RecruitingPhase 1/Phase 2
Study drug for tumors with MTAP loss
This Phase 1/2 trial tests TNG462 (with or without pembrolizumab, depending on the plan) in solid tumors that have lost MTAP. The goal is to check safety and learn whether the treatment can help people with these specific tumor changes.
Chicago, IllinoisAges 18 years+ - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Chicago, IllinoisAges 18 years+
Hear when a new Unresectable Solid Tumor trial opens near Chicago, IL
We’ll email you when one opens near Chicago, IL — at most once a week, no account needed, unsubscribe anytime.
Unresectable Solid Tumor trials in other cities
Where these studies are running near Chicago
Institutions with a site for the recruiting unresectable solid tumor studies listed above.
- University of Chicago · 14 studies
- Ann & Robert H. Lurie Children's Hospital of Chicago · 3 studies
- Northwestern University · 3 studies
- UC Comprehensive Cancer Center at Silver Cross · 3 studies
- University of Chicago Medicine-Orland Park · 3 studies
- University of Illinois · 3 studies
- Ingalls Memorial Hospital · 2 studies
- Midwestern Regional Medical Center · 2 studies
What taking part in a unresectable solid tumor study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there unresectable solid tumor clinical trials near Chicago?
- Yes. We're currently tracking 30 recruiting unresectable solid tumor studies with a site near Chicago, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a unresectable solid tumor study near Chicago?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Chicago to take part?
- Not necessarily. These studies have a site near Chicago, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a unresectable solid tumor trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New unresectable solid tumor studies open near Chicago regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.